Associated Papers
Impact of single nucleotide polymorphisms (R132Q and W120R) on the binding affinity and metabolic activity of CYP2C19 toward some therapeutically important substrates.
Derayea SM et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
Langaee T et al.
Genetic Testing and Molecular Biomarkers, 2019
30758238 (PubMed )
Supplement: sj-pdf-2-gtm-10.1089_gtmb.2018.0298.pdf
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.
Villagra D et al.
Biomarkers in Medicine, 2011
Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips.
Nakamoto K et al.
Pharmacogenetics and Genomics, 2007
The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH et al.
Journal of Human Genetics, 2006
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
British Journal of Clinical Pharmacology, 2001
Select a paper to view details